Wall Street is coming off a losing session after the Federal Reserve paused its interest rate-cutting campaign, leaving its ...

The Nasdaq Composite slid more than 3% in Monday’s trading as a slate of AI-related plays, including chip darling Nvidia, ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Investors continue to hinge their exposure on Fed rate cut expectations. The Dow Jones Industrial Average (DJIA) struck a middling tone on Thursday, churning around the 43,200 handle and testing ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The Dow Jones Industrial Average (DJIA) rose sharply ... This process ensures the integrity, relevance, and value of our content for our readers. Lilly Mwogah is a finance writer specializing in ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all ... Image source: Getty Images. Eli Lilly (NYSE: LLY) is the maker of one of today's ...

Oil futures resume their rally with winter demand and prospects of supply curbs due to U.S. sanctions pushing prices to their highest level since August. "U.S. sanctions against Russia remain the ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. Warren Buffett Sold Over $134 Billion Worth of Stock in 2024, But His Most Recent $200 Million in ...

Despite today's revenue miss, Bernstein stands firm on their long-term outlook for Eli Lilly. This optimism is reflected in the broader analyst consensus, with an average rating of 1.75 (Strong ...